Lancet (London, England) 2014-08-23
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Abstract
Background
Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.
Methods
In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973.
Findings
Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocated ramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care.
Interpretation
Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.
Funding
Eli Lilly.
Related Questions
What do you view as the role for docetaxel+ramucirumab for patients with metastatic NSCLC in light of LUNG-MAP S1800A data?
I still think, at this moment, docetaxel/ramucirumab should be considered standard of care (more below). I would not yet transition to pembro/ram for everyone. A broader issue raised by this trial is whether anti-VEGF drugs, or immunotherapy regimens, alter the efficacy of concurrent or subsequent c...
When giving single agent docetaxel for patients with metastatic NSCLC who have progressed on platinum and immunotherapy, do you stop after 6 cycles or do you continue as long as tolerated and disease is stable?
When giving docetaxel to patients with NSCLC who have disease progression after platinum chemotherapy and immunotherapy, I typically give it in combination with ramucirumab per the REVEL study (Garon et al., PMID 24933332). In this study, patients with NSCLC who had disease progression after platinu...
Assuming an absolute contraindication to immunotherapy and good PS, what is your preferred first line for metastatic squamous cell carcinoma of the lung?
As with many situations we face, there is likely no definite "one" answer to this question. That being said, I tend to like gemcitabine + platinum (usually carboplatin) since it is generally well tolerated and, for those who feel strongly about retaining hair, usually does not lead to hair loss. In ...
What is the preferred second line, systemic therapy for NSCLC patients following first line chemoimmunotherapy?
This is as usual a quite complex question, and for a sophisticated audience such as theMednet readers, I always want to provide a nuanced answer; so here is what my preferred second line systemic therapy currently is:None.None.Still none…Indeed, now that chemo/immunotherapy has become the de facto s...